Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Nami Pandit‐Abid"'
Autor:
Christian Domingo, Klaus F. Rabe, David Price, Guy Brusselle, Michael E. Wechsler, Changming Xia, Nami Pandit-Abid, Rebecca Gall, Paul J. Rowe, Yamo Deniz, Juby A. Jacob-Nara, Amr Radwan
Publikováno v:
ERJ Open Research, Vol 9, Iss 6 (2023)
Background Dupilumab has been shown to improve clinical outcomes long term while reducing oral corticosteroid (OCS) dose in patients with severe OCS-dependent asthma. This post hoc analysis assesses the impact of OCS dose at baseline (≤10 or >10 mg
Externí odkaz:
https://doaj.org/article/4cc17fdbebce48e9b57861c1623c47cb
Autor:
Jonathan Corren, Constance H. Katelaris, Mario Castro, Jorge F. Maspero, Marc Humbert, David M.G. Halpin, Arman Altincatal, Nami Pandit-Abid, Xavier Soler, Amr Radwan, Juby A. Jacob-Nara, Yamo Deniz, Paul J. Rowe
Publikováno v:
ERJ Open Research, Vol 9, Iss 5 (2023)
Background The phase 3 QUEST (NCT02414854) and TRAVERSE (NCT02134028) studies demonstrated the efficacy of dupilumab 200/300 mg versus placebo every 2 weeks for 52 weeks (QUEST) and dupilumab 300 mg up to an additional 96 weeks (TRAVERSE) in patients
Externí odkaz:
https://doaj.org/article/5dd99f3023aa41019700fab408bfb6d4
Autor:
Jorge F Maspero, Claus Bachert, Fernando J Martinez, Nicola A Hanania, Benjamin Ortiz, Naimish Patel, Leda P Mannent, Amy Praestgaard, Nami Pandit-Abid, Shahid Siddiqui, Megan Hardin
Publikováno v:
Journal of Asthma and Allergy. 16:333-342
Jorge F Maspero,1 Claus Bachert,2,3 Fernando J Martinez,4 Nicola A Hanania,5 Benjamin Ortiz,6 Naimish Patel,7 Leda P Mannent,8 Amy Praestgaard,7 Nami Pandit-Abid,9 Shahid Siddiqui,6 Megan Hardin7 1Allergy and Respiratory Research Unit, Fundación C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e287a776cd47a7b950e03edb62ab4625
https://doi.org/10.2147/jaa.s357393
https://doi.org/10.2147/jaa.s357393
Autor:
MARK GURNELL, CHRISTIAN C DOMINGO, KLAUS F RABE, ANDREW MENZIES-GOW, DAVID B PRICE, GUY G BRUSSELLE, MICHAEL E WECHSLER, CHANGMING XIA, NAMI PANDIT-ABID, REBECCA GALL, JUBY A JACOB-NARA, PAUL J ROWE, YAMO DENIZ, SHAHID SIDDIQUI
Publikováno v:
Chest. 162:A1909-A1913
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ad2f600174803bcdd1b824e31edd369
https://doi.org/10.1016/j.chest.2022.08.1587
https://doi.org/10.1016/j.chest.2022.08.1587
Autor:
Lawrence D. Sher, Michael E. Wechsler, Klaus F. Rabe, Jorge F. Maspero, Nadia Daizadeh, Xuezhou Mao, Benjamin Ortiz, Leda P. Mannent, Elizabeth Laws, Marcella Ruddy, Nami Pandit-Abid, Juby A. Jacob-Nara, Rebecca Gall, Paul J. Rowe, Yamo Deniz, David J. Lederer, Megan Hardin
Publikováno v:
Chest. 162:46-55
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af5dd3616c44d5755b2abf4b8500d7c9
https://doi.org/10.1016/j.chest.2022.01.071
https://doi.org/10.1016/j.chest.2022.01.071
Autor:
Klaus F. Rabe, Ian D. Pavord, William W. Busse, Geoffrey L. Chupp, Kenji Izuhara, Arman Altincatal, Rebecca Gall, Nami Pandit‐Abid, Yamo Deniz, Paul J. Rowe, Juby A. Jacob‐Nara, Amr Radwan
Publikováno v:
Allergy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::446e76610fd76985cabc9050afd8ee56
https://doi.org/10.1111/all.15747
https://doi.org/10.1111/all.15747
Autor:
JONATHAN CORREN, MARIO CASTRO, JORGE F MASPERO, MARC HUMBERT, DAVID MG HALPIN, ARMAN ALTINCATAL, NAMI PANDIT-ABID, XAVIER SOLER, SHAHID SIDDIQUI, JUBY A JACOB-NARA, YAMO DENIZ, PAUL J ROWE
Publikováno v:
Chest. 162:A1936-A1938
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7ab963a9bd6c937176263a6379d8bdb
https://doi.org/10.1016/j.chest.2022.08.1603
https://doi.org/10.1016/j.chest.2022.08.1603
Autor:
Bob Geng, Claus Bachert, William W. Busse, Philippe Gevaert, Stella E. Lee, Michael S. Niederman, Zhen Chen, Xin Lu, Faisal A. Khokhar, Upender Kapoor, Nami Pandit-Abid, Juby A. Jacob-Nara, Paul J. Rowe, Yamo Deniz, Benjamin Ortiz
Publikováno v:
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
BACKGROUND: Patients with asthma and/or chronic rhinosinusitis with nasal polyps (CRSwNP) experience recurrent respiratory tract infections. Dupilumab targets type 2 inflammation, a common underlying pathophysiology of both conditions, with proven ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7162df67aba1d81bc2ef4b661077dfe7
https://doi.org/10.1016/j.jaip.2021.12.006
https://doi.org/10.1016/j.jaip.2021.12.006
Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of ICS dose
Autor:
Ian Pavord, Arnaud Bourdin, Alberto Papi, christian domingo, Jonathan Corren, Arman Altincatal, Amr Radwan, Nami Pandit-Abid, Juby A. Jacob-Nara, Yamo Deniz, Paul Rowe, Elizabeth Laws, David Lederer J, Megan Hardin
Background: Dupilumab, a human monoclonal antibody, blocks the shared receptor component for interleukins 4/13, key and central drivers of type 2 inflammation. The LIBERTY ASTHMA TRAVERSE (NCT02134028) open-label extension study demonstrated the long
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::928e1835ac742a5af5466bcc53fb0def
https://doi.org/10.22541/au.167151101.13413168/v1
https://doi.org/10.22541/au.167151101.13413168/v1
Autor:
Lawrence D. Sher, Giovanni Passalacqua, Camille Taillé, Lauren Cohn, Nadia Daizadeh, Nami Pandit-Abid, Xavier Soler, Angela Khodzhayev, Juby A. Jacob-Nara, Yamo Deniz, Paul J. Rowe, Arpita Nag, Yi Zhang
Publikováno v:
Annals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology.
Severe asthma impacts quality of life (QoL), including dyspnea, sleep, and activity limitation. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukins-4/-13, key and central drivers of type 2 inflammation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2582a2e5d4d8f2cb9b96adb64f80cb2
https://pubmed.ncbi.nlm.nih.gov/36509407
https://pubmed.ncbi.nlm.nih.gov/36509407